new york city - november 16, 2004 - · pdf filenew york city - november 16, 2004. 1 2 ......
TRANSCRIPT
1
Nu Skin Enterprises 2004 Investor DayNEW YORK CITY - NOVEMBER 16, 2004
1
2
Please note: This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that represent the company's current expectations and beliefs, including, among other things, financial projections, strategic initiatives, and operational issues. The company wishes to caution and advise readers that these statements are based on assumptions that may not materialize. The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to: (a) continued regulatory scrutiny in China which has from time to time, and could in the future, negatively impact our business, including the suspension of sales activities in stores and the imposition of fines; (b) any inability of the company to effectively manage rapid growth in China, including training and management of a large employed sales force, (c) risk that the Chinese government fails to adapt or further delays adoption of favorable direct selling regulations, or adopts regulations that negatively impacts the company’s current business model there, or that the company fails to obtain a direct selling license under these regulations; (d) regulatory risks associated with the Pharmanex® BioPhotonic Scanner, which could delay or inhibit our use of the scanner if it is determined to be a medical device in any market; (e) any inability to obtain necessary product registrations for its Pharmanex products in a timely manner; (f) risks that could adversely impact the company’s operations or financial results in its markets, including our largest market, Japan, including any increase in the impact of negative market conditions on the company's business, material decreases in executive level and active distributors, adverse changes in exchange rates, or the company's failure to execute effective initiatives in these markets; (g) any failure of planned initiatives including the introduction of the BioPhotonic Scanner in Japan and other markets, to generate interest among distributors and generate sponsoring and selling activities on a sustained basis; (h) adverse publicity related to the company's business, products or industry; and (i) continued competitive pressures in the company's markets. The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission, including the company's most recent amendment to registration statement on form S-3.
3
Blake RoneyChairman
Nu Skin Enterprises 2004 Investor DayNEW YORK CITY - NOVEMBER 16, 2004
2
4
Truman HuntPresident and Chief Executive Officer
Nu Skin Enterprises 2004 Investor DayNEW YORK CITY - NOVEMBER 16, 2004
5
Investor Day Agenda
Blake Roney, ChairmanTruman Hunt, President & CEOCorey Lindley, President - Greater ChinaRobert Conlee, President - North AsiaJoe Chang, President - PharmanexRitch Wood, Chief Financial Officer
3
6
Classic Direct Selling Question:
Is Nu Skin Enterprises a
product or opportunity company?
We’re Both!!
7
Corporate OverviewProduct Divisions
• 2% of H1 04 revenue• e-Tools• Broad product platform
Nu Skin Personal Care
The Beauty of Innovation
• 50% of H1 04 revenue• Skincare = 67%• Nu Skin 180º = $30 million
Pharmanex Nutrition
The Measurable Difference
• 48% of H1 04 revenue• Health and wellness = 80%• LifePak = $250 million
Big Planet Home & BusinessTechnology for Everyone
4
8
Nu Skin Enterprises’ Vision Statement
To become the world’s leading
direct selling company
by paying out more annually in distributor commissions than any other company.
9
How do we distinguish ourselves from other direct selling companies?
• Multiple branded business opportunities
• Global compensation plan
• Higher level of commission payout
• Higher quality sales force
5
10
Direct Sales OverviewSelected Top Direct Selling Companies
Revenue Percent Payout
Avon $6,800M 11%
Amway $6,200M 33%
Mary Kay $1,800M 15%
Tupperware $1,200M 10%
Herbalife $1,200M 33%
Nu Skin Enterprises $1,100M 43%
Pampered Chef $ 700M 10%
Source: Company estimates
11
Nu Skin EnterprisesDirect Sales Model – Distributor Leader Profile
• Seeking high-levels of long-term residual income
• Ability to recruit, train, motivate large sales organization
• Attract a college educated, financially successful demographic
6
12
Is the Direct Selling Industry healthy?
Absolutely.
13
U.S. Direct Selling Retail Sales1993-2003 – In Billions of US$
$15.0$16.6
$17.9$20.8 $22.2 $23.2 $24.5 $25.6 $26.7
$29.6$28.7
$0
$5
$10
$15
$20
$25
$30
$35
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003
Amounts in Billions Source: DSA 2003 Growth & Outlook Survey
7
14
Direct Sales OverviewTop Direct Selling Markets
Market SizeU.S. $ 28.7 BJapan $ 24.5 BKorea $ 4.6 B Mexico $ 2.9 BFrance $ 2.9 B Germany $ 2.5 B UK $ 2.0 B Italy $ 1.9 BBrazil $ 1.9 B
Europe7%
.U.S35%
Japan30%
Asia-other11%
LatinAmerica
11%
Source: WFDSA
15
Country 3 Year % IncreaseRussia 277% China 175%Indonesia 100% India 58% Poland 50%United States 17%Mexico 11%
Direct Sales OverviewRapidly Developing Markets
Source: WFDSA and company estimates
8
16
Sales by Major Product Group, 1997-2003
19974.70%
17.70% 31.9%
18.7%
27.0%
Home/Family Care Personal CareServices/Other WellnessLeisure/Educational
2003
33%
29%
15%
15%
8%
Source: DSA 2003 Growth & Outlook Survey
17
Direct Selling Salesforce Demographics
Male/Female 20% / 80%Part-time/Full-time 85.1% / 14.9%Age over 65 8%Physical Disability 7%African American 13%Hispanic American 13%Asian American 6%
Source: DSA 2004 Growth & Outlook Survey & DSA 2002 Salesforce Survey
9
18
What are the keys to our success?
19
Nu Skin Enterprises’ Strategy Map
10
20
How do we plan to double the size of our business?
• Introduce innovative and unique products
• Provide tools to enhance distributor productivity
• Expand to new geographies & develop existing markets
21
Innovative Products
Tru Face™ Essence ($31M est. ‘04 revenue - introduced 2003) Galvanic Spa™ System IINu Skin Tri-Phasic White
ReishiMax GLp® ($26M est. ‘04 revenue - introduced 2002) Estera™ product line
11
22
Distributor Productivity Retention ToolsPharmanex BioPhotonic Scanner
23
Distributor Productivity ToolsVisia Camera—Advanced Skin Analysis
• Analysis on 6 areas of concern• Individualized plan addressing specific skin challenges • Positive consumer experience in walk-in centers
12
24
Future Key MarketsLatin America & Eastern Europe
Indonesia• Market to open Q2 2005
Russia• Israel opened Nov. 2004• Russia to open H2 2005
Latin America redevelopment• 35% Q3:04 revenue growth• 55% YOY increase in new
distributors during Q3:04
25
Mainland China OverviewEstablished - Q1 2003
• $38 million 2003 revenue
• $105 million - est. 2004 revenue
• Operating in 27 cities in 11 provinces
$0
$20
$40
$60
$80
$100
$120
2003 2004
13
26
Nu Skin Enterprises in ChinaWhy we are excited about this market
• Huge market potential
• Success of competitors to date
• Proven success in other Chinese marketsTaiwan - 6% of D.S. market
Hong Kong - 14% of D.S. market
• Demonstrated success to date
27
Executive SummaryFuture Geographic Profile
2003 Rev. Future
No. Asia $613 M $ 870 MGreater China $135 M $ 550 M No. America $127 M $ 300 MSEA/Pacific $ 76 M $ 125 MEurope $ 32 M $ 75 M Latin America $ 3 M $ 40 MNew Markets $ 100 M
$986M $2,060M
14
28
Corey LindleyExecutive Vice President and
President of Greater China Region
Nu Skin Enterprises 2004 Investor DayNEW YORK CITY - NOVEMBER 16, 2004
29
Mainland China – Direct SellingIndustry & Company History
1990
Direct sales begins in China
1996
$100 Million Est. revenue
1998
Direct sales ban imposed
2001
Accepted intothe WTO
2003
$2 BillionEst. revenue
2004 2005
New direct sales regulations
2000
$500 Million Est. revenue
$5 BillionEst. revenue
Market Research
Business PlanDevelopment
100 Retail Outlets Opened
$105 MillionRevenue
Industry
CompanySource of industry revenue: company estimates
15
30
Mainland China OverviewEstablished - Q1 2003
• $38 million 2003 revenue
• $27 million Q3 04 revenue
• Operating in 27 cities in 11 provinces
• 5,400 sales reps & 200,000 preferred customers
31
Mainland ChinaNu Skin Enterprises 2003 Market Penetration
16
32
Mainland ChinaNu Skin Enterprises 2004 Market Penetration
33
Mainland China – Current OperationsQingdao Retail Outlet Opening
17
34
Mainland China – Current OperationsProduct Offering
Nu Skin Products
• 80% of revenue• 50% of unit volume• 68 SKUs• $12 - $60 price range
Scion Products
• 20% of revenue• 50% of unit volume• 17 SKUs• $4 - $11 price range
35
Mainland China – Current OperationsManufacturing Facilities
• 6.5 million unit capacity• 4.0 million units in 2003• Locally sourced materials• 20% cost savings• Exports begin in 2005• Open Pharmanex facility in
Q4:04
18
36
Mainland China – Current OperationsSales Organization Structure - China vs. Global
Preferred CustomerRetail Discount - $60 minimum purchase
Sales RepresentativeSalary + Bonuses$300/month average
Sales ManagerPerformance-based salaryTop 10 make $10K-$20K/month
Active DistributorWholesale purchaser
Executive DistributorSales volume-based commission$300/month average US Executive
Senior Distributor LeaderLeadership-based commissionsNew Blue Diamonds: $10-$15K/month
China Structure Global Structure
37
Mainland China – Direct SellingLeading Companies – U.S. Based
Revenue ’04 Growth StoresAmway $2,000+ million 100% 130Avon $ 200+ million 40% 7,000+Mary Kay $ 150 million 30% 20+Nu Skin $ 105 million 170% 114
Source: company estimates
19
38
Mainland China – Direct SellingRegulatory Agencies
State CouncilNational governing council – national direct selling regulations
Ministry of Commerce (MofCom)Foreign investment – draft of direct selling regulations
State Administration of Industry and Commerce (SAIC)Regulatory enforcement agency – Anti-pyramiding laws
39
Mainland China – Direct SellingGovernment Relations – Vice Minister of MofCom, Madame Ma
20
40
Mainland China – Direct Selling New Regulations – Company Perspective
1. Independent sales force
2. Retail store requirement
3. Commissions capped
4. Consumable product offering
41
Mainland China – Direct SellingRegulatory Timeline
RegulationsPublished
CompanyApplication
Local MofComApproval
6 to 7 monthTransition
12/31/04 1/31/05 3/1/05
National MofCApproval
6/1/05
Application:1. Financial requirements2. Location requirements3. Structural requirements
12/31/05
Transition:1. Certification test2. Sales force training3. Geographic expansion
21
42
Nu Skin Enterprises – China2005 Business Plan – 2005/2006
Q1:05File direct selling license application
Pharmanex launch w/scanners in walk-in locations
20 new stores, including Beijing and Tainjin
Q2:0520 company stores
25 franchise stores
43
Nu Skin Enterprises – ChinaFranchise Store Business Model
• Partner with qualified sales leaders
• Sales leaders “earn” the right to a store
• Leaders manage store and all employees
• Potential geographic exclusivity
• Minimum sales volume requirements
22
44
Nu Skin Enterprises – China2005 Business Plan – 2005/2006
Q3:0510 new stores
25 franchise stores
Q4:0510 company stores
25 franchise stores
200610 to 20 new company stores
100 more franchise stores
45
Mainland ChinaNu Skin Enterprises 2004 Market Penetration
23
46
60 new stores + 75 franchise stores
Mainland ChinaNu Skin Enterprises 2005 Market Penetration
47
Mainland China – Pharmanex LaunchMarket Potential
Historical impact of Pharmanex launchJapan launch in 1995 - significant revenue impactPharmanex represents 52% or revenuePharmanex 58% of Hong Kong and 50% of Taiwan revenue
Competitive environmentSignificant nutrition market in China Nutrition an important part of Amway China revenue
24
48
Mainland China Overview2003 – 2006 6 Month Revenue – In Millions of US$
$0
$20
$40
$60
$80
$100
H1:03 H2:03 H1:04 H2:04 H1:05 H2:05 H1:06 H2:06
Projected
49
Mainland China Overview2003 – 2008 Projected Annual Revenue – In Millions of US$
$0
$50
$100
$150
$200
$250
$300
2003 2004 2005 2006 2007 2008Projected
25
50
Robert ConleePresident of North Asia
Nu Skin Enterprises 2004 Investor DayNEW YORK CITY - NOVEMBER 16, 2004
51
Nu Skin Enterprises – JapanMarket Overview
Opened Japan in April 1993Combination of products, compensation & management1995 launch of nutrition products – doubled business in 2 years
Direct selling industry in Japan$188/capita direct sales vs. $100/capita direct sales in US*Mature industry, but widely accepted distribution model
Direct selling leader
* Source: World Almanac & WFDSA data
26
52
Top Japan Direct Selling CompaniesIn Billions of Yen
¥0
¥25
¥50
¥75
¥100
¥125
Amway MikiShoji
Nu Skin Charle Summit Noevir FLP Diana Herbalife Avon
53
Nu Skin Enterprises – JapanHealthy Business with Solid Foundation
Consistent revenue generation¥60 to ¥66 billion annual revenue range over the past 5 years
Strong customer base280,000 active purchasers per quarter100,000 subscription orders processed each month – up 25% yoy
Solid distributor leadership base14,000 executive-level distributors
27
54
Nu Skin Enterprises – JapanPrimary Initiatives to Drive Revenue Growth
1. Launch of the Scanner
2. Compensation plan enhancements
3. New products and other marketing initiatives
55
Nu Skin Enterprises – JapanTaiwan Revenue Growth – Impact of Key Initiatives
NT$500
NT$550
NT$600
NT$650
NT$700
NT$750
Q4:02 Q1:03 Q2:03 Q3:03 Q4:03 Q1:04 Q2:04 Q3:04
Compensation Plan Changes
ScannerInitiatives
28
56
Nu Skin Enterprises – JapanTaiwan Subscription Order Growth
0
10,000
20,000
30,000
40,000
Q1:02 Q2:02 Q3:02 Q4:02 Q1:03 Q2:03 Q3:03 Q4:03 Q1:04 Q2:04 Q3:04
Compensation Plan Changes
ScannerInitiatives
Subscriptions are 46% of Total Orders
57
Nu Skin Enterprises – JapanScanner Rollout Plan
Walk-in centers18 scanners in walk-in centers since September 2004Over 40,000 individuals scanned
Convention announcement100 scanners delivered to distributor leaders in December
2005 scanner rollout1,000+ scanners in the field by May 2005
29
58
Nu Skin Enterprises – JapanJapan Subscription Order Growth
40,000
60,000
80,000
100,000
120,000
Q1:02 Q2:02 Q3:02 Q4:02 Q1:03 Q2:03 Q3:03 Q4:03 Q1:04 Q2:04 Q3:04
Subscriptions are 29% of Total Orders
59
Nu Skin Enterprises – JapanCompensation Plan Enhancements
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
Current Plan
LeadershipBonus
ExecutiveBonus
FrontEnd
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
Enhanced Plan
New Leadership
30
60
Market Retention Rates6 Month Distributor Retention
Sept 2003 Sept 2004Hong Kong 34% 60%Taiwan 28% 55%Singapore 26% 44%Japan 43% 43%
61
Nu Skin Enterprises – JapanConvention Initiatives
New product introductionsNu Skin - Tri-Phasic WhitePharmanex - Prime Care: nutritional package for age 40 and abovePharmanex - Targeted nutritional package for womenPharmanex - LifePak reformulation late 2005
Other initiativesPreferred customer programNew simple sign-up processesWeb based sign-up and business tools.
31
62
Nu Skin Enterprises – JapanModest 2005 Revenue Growth and 3 - 5% Long-Term Growth
1. Launch of the scanner
2. Compensation plan enhancements
3. New products and other marketing initiatives
63
Dr. Joe ChangPresident of Pharmanex
Nu Skin Enterprises 2004 Investor DayNEW YORK CITY - NOVEMBER 16, 2004
32
64
Product Development Strategy Unique & Differentiated Products
• Research-based proprietary formulas
• Pharmaceutical grade
• Standardized active ingredients
• Clinical studies
• Unique and proprietary ingredients
• Exclusive relationship with the top 2 ethnobotanists, Drs. Paul Cox and Michael Balick
• “All of the good and none of the bad”
65
Holistic approach to beauty and health • Nutricentials product philosophy
• Science of Youth marketing initiative
• Tegreen and Tru-Face Essence (based on Stanford Medical School research)
• Skin assessment devices that provide a clinical experience without the clinic
Cross-divisional synergyNu Skin & Pharmanex Products
33
The Measurable Difference
67
Health Trends: Nutrition Dilemma
nutritional demands
nutritional deficitsnutritional supply
In a survey of 21,500 people over 70% of people did not even meet 2/3rds of RDA for one or more nutrients.*
* USDA National Food Consumption Survey 1987-88.
ISSUE VALIDATION
34
68
Obesity Inflammation Chronic Stress
Health Trends of the New Millennium
69
Lester Packer Ph.D., USC professor and “Father” of antioxidant research gave the keynote address on “The Antioxidant Network” at the Council for Responsible Nutrition. Speaker at Japan Convention.
Carl Djerassi, Ph.D., Stanford professor and awarded the 2004 American Institute of Chemists Gold Medal on June 17, 2004. Speaker at Singapore “Scan Singapore” event.
Koji Nakanishi, Ph.D., Centennial Professor of Chemistry at Columbia. Discoverer of active ingredient in Bioginkgo.
James Rippe, M.D., Assoc. Prof. of Medicine at Tufts. Completed study on relationship between obesity and skin antioxidant score using the BioPhotonic scanner.
Product Innovation NetworkPharmanex Scientific Advisory Board
35
70
• Over a dozen papers published in peer-reviewed journals in 2003
• 7 patent applications submitted• Presented at 11 scientific conferences
• Developed 139 new quality testing methods• In 2003, Pharmanex conducted 9 human clinical studies, 36
experimental pre-clinical studies, 13 toxicology studies and developed 9 new efficacy testing methods
• Cost effective R&D centers in China
Product Innovation NetworkPharmanex Scientific Staff
71
The basis of science is measurement
Sustaining Product InnovationThe Measurable Difference
36
72
East and West nutritional knowledge
Scientific excellence
Pharmaceutical-grade manufacturing (6S Quality Guarantee)
The Measurable Difference
Product Development PhilosophyThe Measurable Difference
+
+
73
Pharmanex Product StrategyThe Measurable Difference - LifePak
• Double-blind clinical study• First multivitamin product to undergo
trial• Proven bio-availability of ingredients
• Proprietary formulation• Lifepak Challenge, money back
guarantee• Based upon National Research
Council recommendations• Premium source of antioxidants and
other micro-nutrients
37
74
• Third-party validation of product quality relative to 10 other commercially available Reishiproducts
• Proprietary “Cracked Spore”technology• Bio-available active ingredient• Cost effective manufacturing
• Leveraging off Pharmanex China R&D capability
Pharmanex Product StrategyThe Measurable Difference - ReishiMax
75
How do you know whether your nutritional supplements work?
Pharmanex Biophotonic Scanner
Pharmanex Product StrategyThe Measurable Difference
38
76
“… there is a correlation of the concentration of a number of different antioxidants in serum with increasing lifespan of mammalian species. In this case humans had the highest concentration of antioxidants ..."
Dr. Richard Cutler, National Institute of Health
Pharmanex BioPhotonic ScannerThe Importance of Anitoxidants
77
0
500
1,000
1,500
2,000
0
BioPhotonic Scanner
Mean = 25,40632,948 Subjects
Skin Carotenoid Score
Freq
uenc
y
LifePak
5-9 Fruits & Vegetables
Average 2-3 Fruits & Vegetables
Obesity/Smoker
LifePak + 5-9 Fruits & Vegetables
20,000 40,000 60,000 80,000
39
78
The Pharmanex BioPhotonic ScannerInternational Scanner Rollout
Scanner availability in 2004U.S, Taiwan, Hong Kong, Europe
Scanner Availability in 2005Japan, China, South Korea
79
Ritch WoodChief Financial Officer
Nu Skin Enterprises 2004 Investor DayNEW YORK CITY - NOVEMBER 16, 2004
40
80
Revenue(In Millions)
$886
$964$987
$1,115 - $1.120
$850
$950
$1,050
$1,150
2001 2002 2003 2004
Earnings Per share
$0.60
$0.78$0.85
$1.03 - $1.05
$0.45
$0.60
$0.75
$0.90
$1.05
2001 2002 2003 2004
Financial Overview2004 Revenue & EPS Guidance
13% Growth 21 - 24% Growth
81
Revenue(In Millions) $1,165 -
1,200$1,115 - $1.120
$987$964
$886
$800
$900
$1,000
$1,100
$1,200
2001 2002 2003 2004 2005
Earnings Per share$1.13 -$1.20
$0.60
$0.78$0.85
$1.03 - $1.05
$0.40
$0.60
$0.80
$1.00
$1.20
2001 2002 2003 2004 2005
Financial Overview2005 Revenue & EPS Guidance
5 - 7% Growth 10 - 15% Growth
41
82
Financial Overview2005 Revenue & EPS Guidance Assumptions
• Yen rate of ¥112 to the US$
• Gross margin of 82.3 - 82.5%
• Selling expenses of 42.5 - 42.7%
• $6 million convention expense in Q4
• Operating margin of 11.8 - 12.0%
83
¥112 ¥105 ChangeRevenue $1,120M $1,157M 3.3%Gross margin 83.0% 83.4% 0.4%
Selling expense 43.0% 43.0% N/AG&A 29.2% 28.7% 0.5% Operating margin 10.8% 11.7% 0.9%
Excluding hedging and translation gains/(losses):6.25% strengthening of the Yen = 90 bps gain in operating margin
Yen Impact on Results6.25% Strengthen of the Yen/US$ Rate
42
84
• Hedging gains/(losses) offset benefit or detriment to gross margin
• Hedging losses depend on percent of cash flow hedged
• Translation gains/(losses) from asset & liability balances recorded in other income
Yen Impact on ResultsHedging and Other Factors Impacting Results
85
Individual UnitEquipment cost $ 7,500Royalty/allocated costs 3,000Total Cost $10,500
Amortization period 36 months
Cost per month $ 292
Lease revenue per month $ 299
Scanner RolloutFinancial Model
43
86
Gross margin EstimatedScanners Revenue Impact Gross margin
Q4:04 1,500 $1.350M 83.0%
Q1:05 2,500 $2.250M 0.30% 82.70%
Q2:05 3,000 $2.700M 0.15% 82.55%
Q3:05 3,500 $3.150M 0.15% 82.40%
Q4:05 4,000 $3.600M 0.15% 82.25%
Scanner RolloutGross Margin Impact
87
Maintenance/Other CapEx $11 millionScanners (2,000) $15 millionChina – stores/mfg. $13 millionRussia/Indonesia $ 4 millionTotal $43 million
Depreciation & amortization $30 millionCash flow from operations $115 – 120 million
2005 Cash Flow Model$40 to $45 Million in CapEx
44
88
-$50,000
$0
$50,000
$100,000
$150,000
$200,000
$250,000
2001 2002 2003 Total
Uses of Cash72% of Cash Returned to Shareholders After CapEx & Debt
Stock Repurchases47%
Dividend25%
Cash Retained28%
89
Global Subscription Orders
100,000
140,000
180,000
220,000
260,000
300,000
340,000
Dec-02
Mar-03
Jun-0
3
Sep-03
Dec-03
Mar-04
Jun-0
4
Sep-04
109% Growth
45
90
Recurring Revenue Business ModelGrowing the Subscriber Base
$0
$200
$400
$600
$800
$1,000
$1,200
2000 2001 2002 2003 2004 2005
7.5% 16.4% 18.5% 23.8% 41.1% 50.0%
91
Market Retention Rates6 Month Distributor Retention
Sept 2003 Sept 2004Hong Kong 34% 60%Taiwan 28% 55%Singapore 26% 44%
46
92
Revenue by Geography5 Year Profile
Greater China/SE
Asia
North Asia
U.S., Europe, Latin
America
93
2004 Results Future Goal
Gross Margin 83% 83%
Commissions 43% 42%
G&A 29% 26%
Op. Income 11% 15%
Improving ProfitabilityGoal: 15% Operating Margin